Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung Cancer

National Institute of Cancerología

Status: Unknown

Conditions: Circulating Tumor Cells

Study type: Observational

Funder types: Other

Identifiers

NCT01052818

INCAN/OfCA204/SO151/CB451/09

87453 (Other Identifier)

Details and patient eligibility

About

The purpose of the study is to evaluate the association between the number of circulating tumor cells and response to treatment in non small-cell lung cancer patients

Full description

In spite of technological advantages in diagnosis and treatment, lung cancer remains one of the most deadly malignant neoplasias. Moreover, there are no markers for monitoring response to treatment. The objective of the study is to associate the number of circulating tumor cells (CTC) before and after treatment and correlate it with tumor response rate, progression-free survival and overall survival.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histopathologic diagnosis of non small-cell lung cancer
• Clinical stage IV
• ECOG functional status 0 or 1
• No renal function alteration (GFR >50%)
• No hepatic function alteration (ALT and AST less than 2 times its normal value)
• Leucocytes more than 2,000/mcl
• Hemoglobin more than 10mg/dL
• Platelets more than 100,000/mcl

Exclusion criteria

Non-advanced disease

Trial design

200 participants in 1 patient group

Stage IV NSCLC

Description:

Stage IV non small-cell lung cancer patients will be recruited for this protocol